Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol's Scientific Advisory Board. “We are pleased to welcome Ron, with his significant oncology drug development expertise, to the Osmol team,” said Bob Linke, MBA, President and CEO of Osmol Therapeutics. “His medical leadership will be invaluable as we advance OSM-0205 into the clinic based on recent U.S. and German regulatory authority feedback on our development program, including clinical plans, nonclinical studies and manufacturing to support the Phase 2 studies.” “We would also like to express our sincere gratitude to Art for his many contributions during
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024 [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics, Inc. (NASDAQ: TNGX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target raised by analysts at HC Wainwright from $16.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.MarketBeat
TNGX
Earnings
- 11/8/23 - Beat
TNGX
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 144
- 5/2/24 - Form 144
- TNGX's page on the SEC website